Home
Akeso Biopharma Co., Ltd

Akeso Biopharma Co., Ltd Market Share Analysis for May 2026

Health > Biotechnology and Pharmaceuticals

Domainakesobio.com

Year Founded2012

Employees1001 - 5000

Annual Revenue$500M - $1B

Akeso Biopharma Co., Ltd

Akeso Biopharma Co., Ltd (including company regionals)

akesobio.com

See more website traffic and engagement information

Akeso Biopharma Co., Ltd Revenue up to May 2026 is 500M - 1B

revenue generated by Akeso Biopharma Co., Ltd top domains

Akeso Biopharma Co., Ltd top domains revenue over 3 years

Revenue for Akeso Biopharma Co., Ltd top domains

akesobio.com500M - 1B

See more with Sales Intelligence

Total visits to Akeso Biopharma Co., Ltd's top domains

Understand Akeso Biopharma Co., Ltd market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

akesobio.com21.8K

See more with Sales Intelligence

Avg. visit duration in Akeso Biopharma Co., Ltd's top domains

Analyze Akeso Biopharma Co., Ltd engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

akesobio.com00:03:11

See more with Sales Intelligence

Avg. pageviews on Akeso Biopharma Co., Ltd's top domains

See how Akeso Biopharma Co., Ltd keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

akesobio.com6.44

See more with Sales Intelligence

Akeso Biopharma Co., Ltd top competitors by domain

Top similar sites in May 2026, ranked by their affinity

abnova.comCompany NameAbnovaEmployees51 - 200HQTaiwan, TaipeiAnnual revenue$10M - $15MTotal visits25.7KScience and Education > Biology

Top technologies used by Akeso Biopharma Co., Ltd

These are the website technologies, by industry, used by Akeso Biopharma Co., Ltd top domains

Payment & Currencies (4)

PayPal

Conversion & Analytics (3)

Google Analytics

Mobile (3)

Meta Viewport

Advertising (2)

PubMatic

More Technologies

4

See all

News & Signals from Akeso Biopharma Co., Ltd

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAkeso, Inc. is developing Ivonescimab on May 31st '26.Ivonescimab is being developed by Akeso and its US partner, Summit Therapeutics, which licensed Akeso's assets for US$500 million (S$638 million) upfront in late 2022.

NewsAkeso, Inc. attended event 2026 American Association for Cancer Research (AACR) Annual Meeting on Apr 20th '26.HONG KONG, April 20, 2026 /PRNewswire/ - Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that positive Phase II results from the COMPASSION-26 study evaluating cadonilimab, its first-in-class PD-1/CTLA-4 bispecific antibody, in combination with chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma (PDAC), were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

NewsAkeso, Inc. attends event ELCC 2026.Akeso presents updated data on cadonilimab combination therapy in PD-(L)1 inhibitor-resistant advanced NSCLC at ELCC 2026.